| Line Item | 2026-03-31 | Q/Q | Y/Y |
|---|---|---|---|
| R&D Expense | $15K | — | -83.9% |
| SG&A Expense | $1.6M | — | -12.3% |
| Operating Income | -$1.7M | — | +15.7% |
| Interest Expense | $0 | — | — |
| Net Income | -$1.6M | — | -0.9% |
| EPS (Basic) | -$0.01 | — | +0.0% |
| EPS (Diluted) | -$0.01 | — | +0.0% |
| Line Item | 2026-03-31 | Q/Q | Y/Y |
|---|---|---|---|
| Cash & Equivalents | $5.5M | -13.7% | -17.7% |
| Current Assets | $6.1M | -14.5% | -19.8% |
| Total Assets | $6.2M | -14.3% | -19.5% |
| Total Liabilities | $1.1M | +76.9% | -99.2% |
| Stockholders' Equity | $728K | -81.7% | +100.5% |
| Line Item | 2026-03-31 | Q/Q | Y/Y |
|---|---|---|---|
| Operating Cash Flow | -$875K | — | +60.9% |
| Financing Cash Flow | $0 | — | -100.0% |